verified SJR 1,123 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Springer Science + Business...

workspace_premium Q1 — Hematology lock_open Open Access

Current Hematologic Malignancy Reports

Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the jou...

ISSN: 1558-8211

Publisher: Springer Science + Business Media

Category: Hematology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Visit publisher site menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,123 Q1

H-index 48

Acceptance rate pie_chart

33%

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.690 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,123

H-index

Docs (year)

Docs 3y

114

Total refs

1897

Cites 3y

385

Citable 3y

114

Cites/Doc 2y

3.75

Ref/Doc

67.75

Immediate OA

2690 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Coordination of Care in Survivorship After Treatment of Hematological Malignancies - The Journey is Not Over Yet

Where Does Allogeneic Stem Cell Transplantation Fit in the Treatment of Chronic Lymphocytic Leukemia?

Future Therapies for the Myeloproliferative Neoplasms

Familial chronic lymphocytic leukemia

Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases

Ex Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation

Epstein-Barr virus-related lymphoproliferative disorders

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

Elderly Acute Myeloid Leukemia: Assessing Risk

Development and Significance of Mouse Models in Lymphoma Research

Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?"

Current Review on High-Risk Multiple Myeloma

SHOW MORE ARTICLES

Current Approaches to Transplantation for FLT3-ITD AML

A Call to Arms: a Critical Need for Interventions to Limit Pulmonary Toxicity in the Stem Cell Transplantation Patient Population

Controversies in Multiple Myeloma: to Transplant or Not?

Clinical Aspects of Malt Lymphomas

Chronic Myelogenous Leukemia: Monitoring Response to Therapy

Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You

CD30+ Neoplasms of the Skin

Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma

Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review of the Literature and Mini-Meta Analysis

Assessing Quality of Care for the Myelodysplastic Syndromes

Antibody-Based Treatment of Acute Myeloid Leukemia

Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma

FAQs

Current Hematologic Malignancy Reports has an SJR of 1,123 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 2690 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Current Hematologic Malignancy Reports is 33%.

Current Hematologic Malignancy Reports

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Current Hematologic Malignancy Reports?

What is the APC / publication cost?

What is the acceptance rate?